Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-24
2005-05-24
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S232800, C514S321000, C514S422000, C514S439000, C514S440000, C540S576000, C544S146000, C546S202000, C548S525000, C549S042000
Reexamination Certificate
active
06897211
ABSTRACT:
The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-α) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.
REFERENCES:
Postmarketing Adverse Event Data for TNF-alpha Antagonists (Oct. 23, 2001) Stephen A. Paget, MD <http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp>.*
Green (Using TNF alpha technology to treat rheumatoid arthrits) Article (Jul./Aug. 2004) <http://rheumatology.hss.edu/phys/specialreports/pagettnf.asp>.*
Centocor products (Aug. 11, 2004 <http://www.centocor.com/cgi-bin/site/products/prod_remicade.cgi is cited for the statement that>.*
“News & Notices” http://www.psoriasis.org/enbrel.approval.jan02.htm (Jul. 30, 2002).*
Cagniat et al. (Comptes. Rendus des Seances de I'Academie des Sciences, Serie C: Sciences Chimiques (1976). Abstract.*
Aderka, D., Isr. J. Med. Sci., 1991, 27:52-60; “Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis: potential new therapeutic implications.”
Heilig, B. et al., Clinical Investigation 1992: 70:22-27 “Elevated TNF Receptor Plasma Concentrations in Patients with Rheumatoid Arthritis”.
Tomizawa S. et al., Nephron. 1993, 63: 111-112; “TNF inhibitory activity in the urine of chronic renal failure patients with glomerulonephritis.”
Egido J. et al., Kidney Int. Suppl. 1993, 39:59-64; “Role of tumor necrosis factor-alpha in the pathogenesis of glumerular diseases.”
Piguet P.F. et al., Am. J. Pathol. 1993, 143:651-655; “Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis.”
Gauldie J. et al., Thorax, 1993, 48:931-935; “Cytokines and pulmonary fibrosis.”
Badger A.M. et al. Circ. Shock 1994 44(4):188-195; “Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.”
Di Francia M. et al. AM. J. Respir. Crit. Care Med. 1994, 150:1453-1455; “Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.”
Hotamisligil G.S., Spiegelman B.M., Diabetes, 1994, 43:1271-1278; “Tumor necrosis factor alpha: a key component of the obesity-diabetes link.”
Piguet P.F., Vesin C., Eur. respire. J., 1994, 7:515-518; “Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice.”
Bissonnette E. Y. et al., Clin. Exp. Immunol. 1995, 102:78-84; “Inhibition of tumour necrosis factor-alpha (TNF-alpha) release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium.”
M. Feldman et al. Annu. Rev. Immunol. 1996 14:397-440 “Role of Cytokines in Rheumatoid Arthritis”.
Schmidt H. et al. J. Surg. Res. 1996 63(1):143-146; “Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats.”
Kluth D.C., Rees A.J., Semin, Nephrol. 1996, 16:576-582; “Inhibiting inflammatory cytokines.”
Chapman P.T. et al., Arthritis Rheum., 1997, 40:955-965; “Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1.”
Reimund J., Gut 1997, 40;475-480 “In vitro effects of oxpentifylline on Inflammatory Cytokine Release in Patients with Inflammatory Cytokine Release in Patients with Inflammatory Bowel Disease”.
Gruschwitz, M., et al., Journal Rheumatology 1997; 24: 1936-43 “In situ Expression and Serum Levels of Tumor Necrosis Factor-α Receptors in Patients with Early Stages of Systemic Sclerosis”.
Ross S., et al.; Journal of Immunology, 1997, 159:6253-6259, “Suppression on TNFα Expression, Inhibition of TH1 Activity and Amelioration of Collagen-Induced Arthritis by Rolipram”.
Gruschwitz, MS et al., J Rheumatol. 1997; “In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.”
Odeh M. Drugs News Perspect. 11(6) 1998 331-341 “Role of Cytokines in Rheumatoid Arthritis”.
Saricaoglu H. et al. Contact Dermatis 1998, 39(5):244-247; “Prevention of nickel-induced allergic contact reations with pentoxifylline.”
Ackermann L., Harvima I.T. Arch. Dermatol. Res. 1998, 290:353-359; “Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis.”
Stirling D. I. Semin. Cutan. Med. Surg. 1998 17(4):231-242; “Thalidomide and its impact in dermatology.”
Peleman R. A., Kips J.C., Pauwels R.A. Clin. Exp. Allergy 1998 28 Suppl.3:53-56; “Therapeutic activities of theophylline in chronic obstructive pulmonary disease.”
Kapadia S. et al., Cardiol. Clin., 1998, 16:645-656; “The role of cytokines in the failing human heart.”
Liu J.Y. et al., Am. J. Pathol., 1998, 153:1839-1847; “TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers.”
Cheung A. T. et al., Endocrinology, 1998, 139:4928-4935; “An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha.”
Liedthe W., An. of Neurology, 1998 vol. 44; 35-46; “Effective Treatment of Models of Multiple Sclerosis by Matrix Metalloproteinase Inhibitors”.
Taylor R., Multiple Sclerosis: A Rehabilitive Approach, 1998, 9, 3, 525-536,; “Immunologic Aspects of Multiple Sclerosis”.
Oliver S., et al.; Journal of Rheumatology 1998, 25:964-9 “The Effect of Thalidomide and 2 Analogs on Collagen Induced Arthritis”.
Matsukawa A., et al.;Lab Invest 1998; 78:559-569. “Analysis of the Cytokine Network Among Tumor Necrosis Factor α Interleukin-1β, Interleukin-8 and Interleukin-1 Receptor Antagonist in Monosodium Urate Crystal-Induced Rabbit Arthritis”.
Noguchi,M., et al.; gut 1998, 43:203-209; “Secretion Imbalance between Tumor Necrosis Fact or and its inhibitor in Inflammatory bowel disease”.
Shire, MG and Muller GW., Exp. Opin. Ther. Patents. 1998 8(5): 531-544; “TNF-β inhibitors and rheumatoid arthritis”.
Arrieta O et al. Int. J. Exp. Pathol. 1999 80(1):11-16; “Protective effect of pentoxifylline plus thalidomide against septic shock in mice.”
Sasayama S. et al., Cardiovasc Res. 1999, 42:557-564; “New insights into the pathophysiological role for cytokines in heart Failure.”
Dibbs Z. et al., Proc. Assoc. Am. Physicians, 1999, 111:423-428; “Cytokines in heart failure: pathogenetic mechanisms and potential treatment.”
Martel-Pelletier J., Allaeddine N. Pelletier JP Front Biosci, 1999 4:D694-703; “Cytokines and their role in the pathophysiology of osteoarthritis.”
Rutgeerts P. et al.; Gastroenterology., 1999, 117:761-769; “Efficacy and Safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease”.
Sandborn W. and Hanauer S., Inflammatory Bowel Diseases 1999, 5(2):119-133; “Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease; A review of Agents, Pharmacology, Clinical Results and Safety.”
Sykes A.P., et al.; Aliment Pharmacol Ther. 1999, 13:1535-1542 “The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a Erinitrobenzenesulphonic acid rat model of inflammatory bowel disease”.
Corral L
Hrvacic Boska
Mercep Mladen
Mesic Milan
Pesic Dijana
Zupanovic Zeljko
Darby & Darby
Kifle Bruck
Pliva-Istrazivacki Institut d.o.o.
LandOfFree
Thienodibenzoazulene compounds as tumor necrosis factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienodibenzoazulene compounds as tumor necrosis factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienodibenzoazulene compounds as tumor necrosis factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431148